Science Daily·3 min read·medium
CRISPR makes prostate cancer vulnerable to immunotherapy
✦AI Summary
Scientists have developed a CRISPR-based tool that modifies RNA in prostate cancer cells to make them more visible to the immune system. This approach aims to overcome the resistance of 'immune cold' tumors to standard immunotherapy treatments.
Prostate cancer is notoriously difficult to treat with immunotherapy, a type of cancer treatment that helps the immune system identify and destroy tumors. Now, researchers have developed an experimental RNA targeting technology that may make prostate tumors far more vulnerable to an immune attack.
sciencehealthtechnology
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in